Context Therapeutics (CNTX) News Today → Will this $2 AI stock double overnight? (From Behind the Markets) (Ad) Free CNTX Stock Alerts $1.30 -0.11 (-7.80%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineContext Therapeutics (NASDAQ:CNTX) Shares Down 6.4% americanbankingnews.com - April 20 at 2:11 AMContext Therapeutics Takes Bold Step with IND Submission for Groundbreaking Cancer Therapymsn.com - April 3 at 10:55 AMContext Therapeutics, Inc.cnn.com - April 2 at 3:21 PMContext Therapeutics Submits IND For CTIM-76markets.businessinsider.com - April 1 at 10:31 AMContext Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancersglobenewswire.com - April 1 at 7:30 AMBuy Rating Justified by Advances in T Cell Engagers and Context Therapeutics’ Strategic Drug Positioningmarkets.businessinsider.com - March 22 at 9:32 PMCNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023investorplace.com - March 21 at 2:05 PMContext Therapeutics Inc.: Context Therapeutics Reports Full Year 2023 Operating and Financial Resultsfinanznachrichten.de - March 21 at 10:21 AMContext Therapeutics Reports Full Year 2023 Operating and Financial Resultsglobenewswire.com - March 21 at 7:43 AMContext Therapeutics Stock (NASDAQ:CNTX), Short Interest Reportbenzinga.com - December 27 at 9:11 AMContext Therapeutics Stock (NASDAQ:CNTX) Dividends: History, Yield and Datesbenzinga.com - December 27 at 9:11 AMContext Therapeutics (CNTX) Price Target Increased by 21.31% to 3.77msn.com - November 28 at 1:35 AMContext Therapeutics Inc.: Context Therapeutics Reports Third Quarter 2023 Operating and Financial Resultsfinanznachrichten.de - November 10 at 9:33 AMContext Therapeutics prepares for CTIM-76 filing, ends 3Q with enough cash to last through late 2024proactiveinvestors.com - November 10 at 9:33 AMContext Therapeutics GAAP EPS of -$0.37 misses by $0.06msn.com - November 9 at 11:01 PMContext Therapeutics Reports Third Quarter 2023 Operating and Financial Resultsfinance.yahoo.com - November 9 at 6:00 PMHC Wainwright & Co. Upgrades Context Therapeutics (CNTX)msn.com - November 2 at 7:59 AMContext Therapeutics Stock (NASDAQ:CNTX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - November 1 at 10:32 PMContext Therapeutics reveals ‘encouraging’ preclinical data for CTIM-76 tumor treatmentproactiveinvestors.com - October 31 at 3:51 PMContext Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76finance.yahoo.com - October 31 at 9:31 AMContext Therapeutics Inc. (CNTX)finance.yahoo.com - October 8 at 9:06 AMContext Therapeutics (CNTX) Price Target Increased by 45.24% to 3.11msn.com - October 5 at 8:21 AMContext Therapeutics’ Promising CLDN6 Targeting Asset CTIM-76 and Potential Market Valuation Opportunities: An Analyst’s Buy Rating Perspectivemarkets.businessinsider.com - September 28 at 2:54 PMContext Therapeutics says CTIM-76 abstract accepted for presentation at SITC annual meetingproactiveinvestors.com - September 27 at 9:34 AMContext Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meetingfinance.yahoo.com - September 27 at 9:34 AMMaxim Group Initiates Coverage of Context Therapeutics (CNTX) with Buy Recommendationmsn.com - September 11 at 3:17 PMContext Therapeutics Inc.: Context Therapeutics Reports Second Quarter 2023 Operating and Financial Resultsfinanznachrichten.de - August 17 at 2:27 AMContext Therapeutics says it has enough cash to fund operation into late 2024proactiveinvestors.com - August 16 at 5:23 AMContext Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q updatefinance.yahoo.com - August 10 at 5:48 PMContext Therapeutics Reports Second Quarter 2023 Operating and Financial Resultsfinance.yahoo.com - August 9 at 4:46 PMContext Therapeutics to Participate in Two August 2023 Investor Conferencesfinance.yahoo.com - August 1 at 5:41 PMHC Wainwright & Co. Reiterates Context Therapeutics (CNTX) Prior Recommendationmsn.com - June 7 at 12:14 AMWill Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?finance.yahoo.com - June 3 at 10:10 AMDirector at Context Therapeutics Acquires Company Stock Options Worth 25,000 Sharesbenzinga.com - June 1 at 3:40 PMASCO 2023 Spotlight: Claudin 6 Anticipated To Shinebenzinga.com - May 16 at 5:11 PMContext Therapeutics Inc.: Context Therapeutics Reports First Quarter 2023 Operating and Financial Resultsfinanznachrichten.de - May 11 at 1:34 PMContext Therapeutics (CNTX) Gets a Hold from H.C. Wainwrightmarkets.businessinsider.com - May 11 at 8:33 AMContext Therapeutics Reports First Quarter 2023 Operating and Financial Resultsfinance.yahoo.com - May 10 at 5:32 PMContext Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual Meetingproactiveinvestors.com - April 24 at 9:29 AMSignificant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Differencefinance.yahoo.com - April 18 at 1:46 PMH.C. Wainwright Remains a Hold on Context Therapeutics (CNTX)markets.businessinsider.com - April 18 at 8:06 AMContext Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting, will host webinarproactiveinvestors.com - April 14 at 4:34 PMSignificant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ: CNTX) Plans To Make A Differencebenzinga.com - April 14 at 11:32 AMContext Therapeutics to Participate in Two April 2023 Investor Conferencesfinance.yahoo.com - April 3 at 8:29 AMContext Therapeutics discontinues development of lead drug candidate, shifts to new targetbizjournals.com - March 24 at 1:09 PMContext Therapeutics announces pipeline update with FY 2022 financial resultsproactiveinvestors.com - March 23 at 12:54 PMContext Therapeutics Inc.: Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updatesfinanznachrichten.de - March 23 at 7:54 AMH.C. Wainwright downgrades Context Therapeutics (CNTX) to a Holdmarkets.businessinsider.com - March 23 at 7:54 AMContext Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updatesfinance.yahoo.com - March 22 at 5:42 PMContext Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meetingproactiveinvestors.com - March 15 at 1:36 PM Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall. Click here now for the full details of this stock that’s set to rocket in the AI revolution… CNTX Media Mentions By Week CNTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTX News Sentiment▼0.670.44▲Average Medical News Sentiment CNTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTX Articles This Week▼10▲CNTX Articles Average Week Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GRFS News LVTX News MYNZ News NLSP News PHVS News PROC News QLI News TLSA News ACONW News DRTSW News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
